"There is a possibility that, as the data matures, paxalisib could end up showing a significant improvement in OS relative to the control arm. KZA could certainly approach the regulators (FDA, EMA )and seek approval of paxalisib for GBM if that were the case..."
"...A more likely scenario is that paxalisib demonstrates a significantly improved progression free (PFS) when compared to the control arm.."
Good find @dking99 this deserves its own thread.. I was wondering what the cohort numbers were 150 is quite a cohort and the data would be compelling on those numbers you could assume.
KZA Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
